Table 4.
Association between nutrient supplementation and seroprevalence in 6 months old children
| Outcome | Number of children seropositive/total number of children | Comparison between LNS and IFA group | Comparison between LNS and MMN group | Comparison between MMN and IFA group | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| IFAa | MMNb | LNSc | P valued | OR (95% CI) | P valuee | OR (95% CI) | P valuee | OR (95% CI) | P valuee | |
| MSP-1f 19kD | 43/145 (29.7%) |
44/140 (31.4%) |
41/147 (27.9%) |
0.806 | 0.96 (0.74, 1.23) | 0.739 | 0.84 (0.51, 1.40) | 0.512 | 1.07 (0.64, 1.77) | 0.804 |
| Adjusted modelg | 0.97 (0.73, 1.28) | 0.808 | 0.86 (0.49, 1.49) | 0.583 | 1.01 (0.57, 1.76) | 0.981 | ||||
| MSP-2h | 38/145 (26.2%) |
40/140 (28.6%) |
36/147 (24.5%) |
0.734 | 0.96 (0.73, 1.24) | 0.736 | 0.81 (0.48, 1.37) | 0.434 | 1.07 (0.63, 1.80) | 0.807 |
| Adjusted modelg | 0.98 (0.74, 1.31) | 0.893 | 0.80 (0.45, 1.42) | 0.447 | 1.09 (0.62, 1.94) | 0.764 | ||||
| EBA-175i | 15/145 (10.3%) |
20/140 (14.3%) |
13/147 (8.9%) |
0.320 | 0.92 (0.62, 1.35) | 0.663 | 0.58 (0.28, 1.22) | 0.152 | 1.34 (0.65, 2.76) | 0.426 |
| Adjusted modelg | 0.96 (0.63, 1.47) | 0.857 | 0.54 (0.25, 1.18) | 0.120 | 1.53 (0.70, 3.37) | 0.289 | ||||
| Rh2A9j | 9/145 (6.21%) |
3/140 (2.14%) |
2/147 (1.4%) |
0.044 | 0.46 (0.21, 0.99) | 0.047 | 0.63 (0.10, 3.83) | 0.616 | 0.33 (0.09, 1.23) | 0.098 |
| Adjusted modelg | 0.48 (0.21, 1.06) | 0.070 | 0.79 (0.12, 5.42) | 0.814 | 0.34 (0.09, 1.30) | 0.114 | ||||
| Schizont extract | 68/145 (46.9%) |
67/140 (47.86%) |
67/147 (45.6%) |
0.927 | 0.97 (0.77, 1.23) | 0.821 | 0.91 (0.57, 1.45) | 0.699 | 1.07 (0.67, 1.71) | 0.774 |
| Adjusted modelg | 0.91 (0.70, 1.18) | 0.468 | 0.89 (0.53, 1.51) | 0.677 | 0.97 (0.58, 1.63) | 0.923 | ||||
| VSAk of E8B parasite line | 31/145 (21.4%) |
39/140 (27.9%) |
35/147 (23.8%) |
0.437 | 1.09 (0.83, 1.43) | 0.552 | 0.80 (0.47, 1.36) | 0.402 | 1.52 (0.88, 2.64) | 0.134 |
| Adjusted modelg | 1.01 (0.74, 1.37) | 0.957 | 0.70 (0.38, 1.26) | 0.233 | 1.55 (0.86, 2.80) | 0.146 | ||||
| VSA of R29 parasite line | 14/145 (9.7%) |
12/140 (8.6%) |
11/147 (7.5%) |
0.803 | 0.86 (0.57, 1.30) | 0.470 | 0.83 (0.35, 1.94) | 0.659 | 0.88 (0.39, 1.98) | 0.756 |
| Adjusted modelg | 0.76 (0.48, 1.20) | 0.234 | 0.69 (0.27, 1.74) | 0.427 | 0.91 (0.38, 2.14) | 0.822 | ||||
| VSA of 3D7 parasite line | 27/145 (18.6%) |
33/140 (23.6%) |
34/147 (23.1%) |
0.530 | 1.16 (0.87, 1.54) | 0.313 | 0.97 (0.56, 1.69) | 0.924 | 1.35 (0.76, 2.41) | 0.301 |
| Adjusted modelg | 1.04 (0.75, 1.43) | 0.829 | 0.89 (0.48, 1.65) | 0.721 | 1.24 (0.66, 2.31) | 0.501 | ||||
aIron and folic acid
bMultiple micronutrients
clipid based nutrient supplements
d P value calculated using the Chi2 test
e P value calculated using logistic regression reporting Odds Ratios (OR) and 95% Confidence intervals (CI)
fMerozoite surface protein 1
gP value calculated using multivariate logistic regression reporting odds ratios (OR) while adjusting for maternal BMI at enrolment, duration of gestation (from enrolment to delivery), number of pregnancies, sex of the child, maternal education, socioeconomic status, study site, maternal anaemic status at enrolment, maternal HIV status and bed net use by children
hMerozoite surface protein 2
iErythrocyte binding antigen 175
jReticulocyte binding protein homologue 2A
kVariant surface antigens
Significant P values <0.05 are indicated in italics